Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola
Michele
M
Institute of Hematology and Medical Oncology L & A Seràgnoli, University of Bologna, Italy. acute@med.unibo.it
Martinelli
Giovanni
G
Rondoni
Michela
M
Ottaviani
Emanuela
E
Piccaluga
Pier Paolo
PP
Ricci
Paolo
P
Visani
Giuseppe
G
Baccarani
Michele
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology; D002908:Chronic Disease; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000097:blood*; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000097:blood*
D000970:Antineoplastic Agents; D001549:Benzamides; C479818:FIP1L1 protein, human; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha